Marketing-authorisation holder · United States
Rigel Pharms
3 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| GAVRETO100mg · Capsule | Pralsetinib | United States | Marketed | 2020 |
| REZLIDHIA150mg · Capsule | Olutasidenib | United States | Marketed | 2022 |
| TAVALISSE100mg base | 150mg base · Tablet | Fostamatinib | United States | Marketed | 2018 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 3 | 3 | 0 | CompaniesAll medicines |
Top substances
The active substances in most of its medicines.